



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/403,625	02/07/2000	WINOK DEBYER	550-392	7510

23117 7590 03/26/2003

NIXON & VANDERHYE, PC  
1100 N GLEBE ROAD  
8TH FLOOR  
ARLINGTON, VA 22201-4714

EXAMINER
----------

FRONDA, CHRISTIAN L

ART UNIT	PAPER NUMBER
----------	--------------

1652

DATE MAILED: 03/26/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.  
**09/403,625**

Applicant(s)  
**Debyser et al.**

Examiner  
**Christian L. Fronda**

Art Unit  
**1652**



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 48-57 is/are pending in the application.
- 4a) Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 48-57 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claims \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☒ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☒ All b) ☐ Some\* c) ☐ None of:  
1. ☒ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\*See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). \_\_\_\_\_ 6) ☐ Other:

Art Unit: 1652

### DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicants' submission filed on 12/17/2002 (Paper No. 13) has been entered.
2. Claims 48-57 are under consideration in this Office Action.

### *Claim Rejections - 35 U.S.C. § 112, 1st Paragraph*

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:  
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
4. Claims 48-57 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicants' arguments filed 12/17/2002 (Paper No. 13) have been fully considered but they are not persuasive. Applicants' position is that the specification provides an adequate written description of claimed protein to enable the skilled artisan to recognize that Applicants were in possession of the claimed invention. The Examiner disagrees with Applicants' position.

The specification only describes a xylanase inhibitor which is a water-soluble, alkaline protein having two subunits with a partial N-terminal amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2, a molecular weight of 40-43 kDa, and pI of greater than about 7.0. The claims are directed to any proteinic or glycoprotein xylanase inhibitor having any structure or amino acid sequence with a pI of greater than 7.0 and a molecular weight of 40-43 kDa. There is no disclosure of any particular structure to function/activity relationship in the single disclosed species. The specification also fails to describe additional representative species of these proteins by any identifying structural characteristics or properties for which no predictability of structure is apparent. Given this lack of additional representative species as encompassed by the claims, Applicants have failed to sufficiently describe the claimed invention, in such full, clear,

Art Unit: 1652

concise, and exact terms that a skilled artisan would recognize Applicants were in possession of the claimed invention.

Amending the claims to recite that the claimed inhibitor is a water-soluble, alkaline protein having two subunits with an amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2, the molecular weight of 40-43 kDa, and pI of greater than about 7.0 may overcome the rejection.

5. Claims 48-57 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for xylanase inhibitor which is a water-soluble, alkaline protein having two subunits with a partial N-terminal amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2, a molecular weight of 40-43 kDa, and pI of greater than about 7.0, does not reasonably provide enablement for any other embodiment. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Applicants' arguments filed 12/17/2002 (Paper No. 13) have been fully considered but they are not persuasive. Applicants' position is that the specification provides adequate guidance for preparing extracts and using assays to screen for xylanase inhibitors such that one of skill in the art may practice the claimed invention using routine experimentation. The Examiner disagrees with Applicants' position.

The specification teaches a xylanase inhibitor which is a water-soluble, alkaline protein having two subunits with a partial N-terminal amino acid sequence of SEQ ID NO: 1 and SEQ ID NO: 2, a molecular weight of 40-43 kDa, and pI of greater than about 7.0. The nature and breadth of the claims encompass any proteinic or glycoprotein xylanase inhibitor having any structure or amino acid sequence with a pI of greater than 7.0 and a molecular weight of 40-43 kDa. Knowledge regarding the specific structure of any proteinic or glycoprotein xylanase inhibitor having any structure or amino acid sequence with a pI of greater than 7.0 and a molecular weight of 40-43 kDa is lacking.

The amount of experimentation to make the claimed inventions is enormous. Such experimentation entails screening vast numbers of organisms for any proteinic or glycoprotein having any structure or amino acid sequence with a pI of greater than 7.0 and a molecular weight of 40-43 kDa and determining whether the protein or glycoprotein is still able to inhibit xylanase enzyme activity. Since routine experimentation does not include screening vast numbers of organisms for a specific organism which contains any proteinic or glycoprotein having any structure or amino acid sequence with a pI of greater than 7.0 and a molecular weight of 40-43 kDa which is able to inhibit xylanase enzyme activity, where the expectation of identifying any proteinic or glycoprotein having any structure or amino acid sequence with a pI of greater than 7.0 and a molecular weight of 40-43 kDa which is able to inhibit xylanase enzyme activity is unpredictable, the Examiner finds that one skilled in the art would require additional guidance, such as the specific amino acid sequence of the claimed protein or glycoprotein. Without such a

Art Unit: 1652


guidance, the experimentation left to those skilled in the art is undue.

*Conclusion*

6. No claim is allowed.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L. Fronda whose telephone number is (703)305-1252. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached at (703)308-3804. The fax phone number for this Group is (703)308-0294. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703)308-0196.

CLF

  
PONNATHAPURA ACHUTAMURTHY  
SUPERVISORY PATENT EXAMINER  
ART UNIT 1600